keyword
https://read.qxmd.com/read/38327733/exploring-promising-therapies-for-non-alcoholic-fatty-liver-disease-a-clinicaltrials-gov-analysis
#1
REVIEW
Omar E Hegazi, Samer O Alalalmeh, Moyad Shahwan, Ammar Abdulrahman Jairoun, Mansour M Alourfi, Ghfran Abdulrahman Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Abdulrahman Aljehani, Abdulmalik Mohammed Alsabban, Mohammad Almtrafi, Ysear Abdulaziz Zakri, Abdullah AlMahmoud, Khalid Mohammed Alghamdi, Ahmed M Ashour, Nasser M Alorfi
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common disease and has been increasing in recent years. To date, no FDA-approved drug specifically targets NAFLD. METHODS: The terms "Non-alcoholic Fatty Liver Disease" and "NAFLD" were used in a search of ClinicalTrials.gov on August 24, 2023. Two evaluators independently examined the trials using predetermined eligibility criteria. Studies had to be interventional, NAFLD focused, in Phase IV, and completed to be eligible for this review...
2024: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/38169889/comparison-of-changes-in-adipokine-and-inflammatory-cytokine-levels-in-patients-with-newly-diagnosed-type-2-diabetes-treated-with-exenatide-insulin-or-pioglitazone-a-post-hoc-study-of-the-confidence-trial
#2
JOURNAL ARTICLE
Xubin Yang, Hongrong Deng, Jing Lv, Xueyan Chen, Longyi Zeng, Jianping Weng, Hua Liang, Wen Xu
BACKGROUND: Adipokines and inflammatory cytokines (ADICs) play important roles in type 2 diabetes mellitus (T2DM). This study aimed to compare the changes of ADIC levels (ΔADICs) in patients with newly diagnosed T2DM treated with different antihyperglycemic agents, and further investigate the impact of these changes on metabolic indices, β-cell function and insulin resistance (IR). METHODS: Four hundred and sixteen patients with newly diagnosed T2DM from 25 centers in China randomly received 48-week intervention with exenatide, insulin or pioglitazone...
January 15, 2024: Heliyon
https://read.qxmd.com/read/37974258/comparative-effectiveness-of-multiple-different-treatment-regimens-for-nonalcoholic-fatty-liver-disease-with-type-2-diabetes-mellitus-a-systematic-review-and-bayesian-network-meta-analysis-of-randomised-controlled-trials
#3
JOURNAL ARTICLE
Manjun Deng, Yonghao Wen, JingXin Yan, Yichen Fan, Zhixin Wang, Ruixia Zhang, Li Ren, Yinggui Ba, Haijiu Wang, Qian Lu, Haining Fan
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely related and mutually contribute to the disease's development. There are many treatment options available to patients. We provide a comprehensive overview of the evidence on the treatment effects of several potential interventions for NAFLD with T2DM. METHODS: This systematic review and network meta-analysis included searches of PubMed, Embase, Cochrane Library, and Web of Science from inception to June 30, 2023, for randomised controlled trials of treatment of NAFLD with T2DM...
November 16, 2023: BMC Medicine
https://read.qxmd.com/read/37683311/data-driven-subgroups-of-newly-diagnosed-type-2-diabetes-and-the-relationship-with-cardiovascular-diseases-at-genetic-and-clinical-levels-in-chinese-adults
#4
JOURNAL ARTICLE
Weihao Wang, Tong Jia, Yiying Liu, Hongrong Deng, Zihao Chen, Jing Wang, Zhaoxu Geng, Ran Wei, Jingtao Qiao, Yanhua Ma, Xun Jiang, Wen Xu, Jian Shao, Kaixin Zhou, Ying Li, Qi Pan, Wenying Yang, Jianping Weng, Lixin Guo
BACKGROUND: To subgroup Chinese patients with newly diagnosed type 2 diabetes (T2D) by K-means cluster analysis on clinical indicators, and to explore whether these subgroups represent different genetic features and calculated cardiovascular risks. METHODS: The K-means clustering analysis was performed on two cohorts (n = 590 and 392), both consisting of Chinese participants with newly diagnosed T2D. To assess genetic risks, multiple polygenic risk scores (PRSs) and mitochondrial DNA copy numbers (mtDNA-CN) were calculated for all participants...
August 30, 2023: Diabetes & Metabolic Syndrome
https://read.qxmd.com/read/37011023/simultaneous-analysis-of-antihyperglycemic-small-molecule-drugs-and-peptide-drugs-by-means-of-dual-liquid-chromatography-high-resolution-mass-spectrometry
#5
JOURNAL ARTICLE
Aline C Vollmer, Lea Wagmann, Armin A Weber, Markus R Meyer
OBJECTIVES: The study aimed to evaluate dual liquid chromatography (LC) coupled to high-resolution mass spectrometry (HRMS) for the simultaneous analysis of small and large molecule drugs by development and application of a validated bioanalytical method. METHODS: The oral antihyperglycemic drugs (OAD) dapagliflozin, empagliflozin, glibenclamide, glimepiride, metformin, pioglitazone, repaglinide, saxagliptin, sitagliptin, and vildagliptin, as well as the antihyperglycemic peptides exenatide, human insulin, insulin aspart, insulin degludec, insulin detemir, insulin glargine, insulin glulisine, insulin lispro, and semaglutide were included in the analytical procedure...
April 4, 2023: Clinical Chemistry and Laboratory Medicine: CCLM
https://read.qxmd.com/read/36869381/the-effects-of-first-line-pharmacological-treatments-for-reproductive-outcomes-in-infertile-women-with-pcos-a-systematic-review-and-network-meta-analysis
#6
JOURNAL ARTICLE
Ge Peng, Zhe Yan, Yuqi Liu, Juan Li, Jinfang Ma, Nanwei Tong, Yan Wang
BACKGROUND: Polycystic ovarian syndrome (PCOS) is one of the most common causes of infertility in reproductive-age women. However, the efficacy and optimal therapeutic strategy for reproductive outcomes are still under debate. We conducted a systematic review and network meta-analysis to compare the efficacy of different first-line pharmacological therapies in terms of reproductive outcomes for women with PCOS and infertility. METHODS: A systematic retrieval of databases was conducted, and randomized clinical trials (RCTs) of pharmacological interventions for infertile PCOS women were included...
March 3, 2023: Reproductive Biology and Endocrinology: RB&E
https://read.qxmd.com/read/36629649/effects-of-antidiabetics-and-exercise-therapy-on-suppressors-of-cytokine-signaling-1-suppressors-of-cytokine-signaling-3-and-insulin-receptor-substrate-1-molecules-in-diabetes-and-obesity
#7
JOURNAL ARTICLE
Ersin Akarsu, Zeynel Abidin Sayiner, Sibel Oğuzkan Balcı, Can Demirel, Zehra Bozdag, Murat Korkmaz, Ibrahim Yılmaz
OBJECTIVE: Pathological destruction of insulin signaling molecules such as insulin receptor substrate, especially due to the increase in suppressors of cytokine signaling molecules, has been demonstrated in experimental diabetes. The contribution of suppressors of cytokine signaling proteins to the development of insulin resistance and the effects of antidiabetic drugs and exercise on suppressors of cytokine signaling proteins are not clearly known. METHODS: A total of 48 Wistar albino adult male rats were divided into six groups: control group, obese group with diabetes, obese diabetic rats treated with metformin, obese diabetic rats treated with pioglitazone, obese diabetic rats treated with exenatide, and obese diabetic rats with applied exercise program...
January 9, 2023: Revista da Associação Médica Brasileira
https://read.qxmd.com/read/36555387/the-influence-of-lifestyle-and-treatment-on-oxidative-stress-and-inflammation-in-diabetes
#8
REVIEW
Magdalena Wronka, Julia Krzemińska, Ewelina Młynarska, Jacek Rysz, Beata Franczyk
Diabetes is considered a new pandemic of the modern world, and the number of sufferers is steadily increasing. Sustained hyperglycemia promotes the production of free radicals and leads to persistent, low-grade inflammation. Oxidative stress causes mitochondrial destruction, which along with activation of the hexosamine pathway, nuclear factor-κB (Nf-κb), p38 mitogen-activated protein kinase (p38 MAPK), c-jun NH2 terminal kinase/stress-activated protein kinase (JNK/SAPK) or toll-like receptors (TLRs), leads to pancreatic β-cell dysfunction...
December 12, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/36384763/drugs-for-type-2-diabetes
#9
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 14, 2022: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36342972/longitudinal-assessment-of-the-quality-of-life-and-patterns-of-antidiabetic-medication-use-in-patients-with-type-2-diabetes-saudi-arabia-perspective-discover-study
#10
JOURNAL ARTICLE
Khalid Al-Rubeaan, Faisal Banah, Fayez G Alruwaily, Eman Sheshah, Dhekra Alnaqeb, Awad M AlQahtani, Diaa Ewais, Nassr Al Juhani, Abdul-Hameed Hassan, Amira M Youssef
Objectives: Patients with type 2 diabetes nowadays have a wide range of new antidiabetic medications with better efficacy and safety. Physicians' attitude toward selecting antidiabetic medications to reach targeted glycemic control and better quality-of-life (QOL) has not been studied prospectively. The global DISCOVER study aims to comprehensively provide a real-world assessment of the treatment pattern changes for patients with type 2 diabetes, in addition to QOL assessment. The Kingdom of Saudi Arabia was one of the countries participating in the DISCOVER study program...
November 7, 2022: Current Medical Research and Opinion
https://read.qxmd.com/read/35971924/diagnosis-and-management-of-hyperglycaemia-in-patients-treated-with-antipsychotic-drugs
#11
JOURNAL ARTICLE
Marcin Kosmalski, Monika Różycka-Kosmalska, Marcin Basiak, Bogusław Okopień, Tadeusz Pietras
Research results indicate the presence of an association between mental disorders, certain antipsychotics, and the risk of developing prediabetes (preDM) and specific type diabetes mellitus (DM). However, there are no precise recommendations for their diagnosis and treatment. The obtained data suggest the necessity to perform diagnostics of carbohydrate disorders at the onset of the first symptoms of psychosis, even before the implementation of antipsychotic drugs, and the oral glucose tolerance test (OGTT) seems to be the optimal tool...
August 16, 2022: Endokrynologia Polska
https://read.qxmd.com/read/35723225/fgf21-contributes-to-metabolic-improvements-elicited-by-combination-therapy-with-exenatide-and-pioglitazone-in-patients-with-type-2-diabetes
#12
RANDOMIZED CONTROLLED TRIAL
Ricardo J Samms, Christine C Cheng, Marcel Fourcaudot, Sami Heikkinen, Ahmed Khattab, John Adams, Eugenio Cersosimo, Curtis Triplitt, Curtis Puckett, Kostas Tsintzas, Andrew C Adams, Muhammad A Abdul-Ghani, Ralph A DeFronzo, Luke Norton
Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined whether FGF21 contributed to the metabolic improvements observed following treatment of patients with T2D with either triple (metformin/pioglitazone/exenatide) or conventional (metformin/insulin/glipizide) therapy for 3 yr. Forty-six patients with T2D were randomized to receive either triple or conventional therapy to maintain HbA1c < 6...
August 1, 2022: American Journal of Physiology. Endocrinology and Metabolism
https://read.qxmd.com/read/35581905/type-2-diabetes-subgroups-and-response-to-glucose-lowering-therapy-results-from-the-edict-and-qatar-studies
#13
JOURNAL ARTICLE
Tamam Abdul-Ghani, Curtiss Puckett, Osama Migahid, Siham Abdelgani, Ayman Migahed, John Adams, Curtis Triplitt, Ralph DeFronzo, Amin Jayyousi, Muhammad Abdul-Ghani
AIM: To examine the efficacy of glucose-lowering medications in subgroups of patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: Cluster analysis was performed in participants in the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) study and the Qatar study using age, body mass index (BMI), glycated haemoglobin (HbA1c), and homeostatic model assessment of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β)...
September 2022: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/35072848/the-effects-of-metformin-pioglitazone-exenatide-and-exercise-on-fatty-liver-in-obese-diabetic-rats-the-role-of-irs-1-and-socs-3-molecules
#14
JOURNAL ARTICLE
Kemal Ozan Lule, Ersin Akarsu, Zeynel Abidin Sayiner, Nezihe Otay Lule, Sibel Oguzkan Balci, Can Demirel, Zehra Bozdag, Murat Korkmaz, Ibrahim Yilmaz
BACKGROUND: Obesity-induced inflammation mechanism is seen as a mechanism that may be the cause of insulin resistance and non-alcoholic fatty liver disease (NAFLD). Pathological destruction of insulin signaling molecules such as insulin receptor substrate proteins (IRS), especially due to the increase of cytokine signal suppressors (SOCS), has been demonstrated in experimental diabetes. The aim of this study was to determine the effects of metformin, pioglitazone, exenatide and exercise treatments used in type 2 diabetes on fatty liver and the role of Irs-1 and Socs3 molecules in this process in obese diabetic rats...
February 2022: Inflammopharmacology
https://read.qxmd.com/read/35014145/combination-therapy-with-pioglitazone-exenatide-metformin-reduces-the-prevalence-of-hepatic-fibrosis-and-steatosis-the-efficacy-and-durability-of-initial-combination-therapy-for-type-2-diabetes-edict
#15
JOURNAL ARTICLE
Olga Lavynenko, Muhammad Abdul-Ghani, Mariam Alatrach, Curtiss Puckett, John Adams, Siham Abdelgani, Naim Alkhouri, Curtis Triplitt, Geoffrey D Clarke, Juan A Vasquez, Jinqi Li, Eugenio Cersosimo, Amalia Gastaldelli, Ralph A DeFronzo
AIM: To compare the efficacy of triple therapy (metformin/exenatide/pioglitazone) versus stepwise conventional therapy (metformin → glipizide → glargine insulin) on liver fat content and hepatic fibrosis in newly diagnosed, drug-naïve patients with type 2 diabetes. METHODS: Sixty-eight patients completed the 6-year follow-up and had an end-of-study (EOS) FibroScan to provide measures of steatosis (controlled attenuation parameter [CAP] in dB/m) and fibrosis (liver stiffness measurement [LSM] in kPa); 59 had magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to measure liver fat...
May 2022: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/34721294/effects-of-anti-diabetic-drugs-on-fracture-risk-a-systematic-review-and-network-meta-analysis
#16
JOURNAL ARTICLE
Yu-Sheng Zhang, Yan-Dan Zheng, Yan Yuan, Shi-Chun Chen, Bao-Cheng Xie
PURPOSE: Available data on the effects of anti-diabetic drugs on fracture risk are contradictory. Therefore, our study aimed to analyze all available data on the effects of anti-diabetic drugs on fracture risk in type 2 diabetes mellitus (T2DM) patients. METHODS: Embase, Medline, ClinicalTrials.gov, and Cochrane CENTRAL were searched for relevant trials. All data analyses were performed with STATA (12.0) and R language (3.6.0). Risk ratio (RR) with its 95% confidence interval (CI) was calculated by combining data for the fracture effects of anti-diabetic drugs, including sodium-glucose co-transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, α-glucosidase inhibitors, thiazolidinediones, biguanides, insulin, and sulfonylureas...
2021: Frontiers in Endocrinology
https://read.qxmd.com/read/34713480/impact-of-pharmacological-interventions-on-insulin-resistance-in-women-with-polycystic-ovary-syndrome-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#17
REVIEW
Mohammed A Abdalla, Najeeb Shah, Harshal Deshmukh, Amirhossein Sahebkar, Linda Östlundh, Rami H Al-Rifai, Stephen L Atkin, Thozhukat Sathyapalan
OBJECTIVE: Polycystic ovary syndrome (PCOS) is a complex endocrine condition affecting women of reproductive age. It is characterized by insulin resistance and is a major risk factor for type 2 diabetes mellitus (T2DM). The objective was to review the literature on the effect of different pharmacological interventions on insulin resistance in women with PCOS. DESIGN: We searched PubMed, MEDLINE, Scopus, Embase, Cochrane library and the Web of Science in April 2020 and updated in March 2021...
March 2022: Clinical Endocrinology
https://read.qxmd.com/read/34343296/insulin-secretion-predicts-the-response-to-antidiabetic-therapy-in-patients-with-new-onset-diabetes
#18
JOURNAL ARTICLE
S Abdelgani, C Puckett, J Adams, C Triplitt, R A DeFronzo, M Abdul-Ghani
AIM: To identify predictors for individualization of antidiabetic therapy in patients with new onset T2DM. RESEARCH DESIGN AND METHODS: 261 drug naïve participants in the EDICT study, with new onset diabetes, were randomized in a single-center study to receive: (1) metformin followed by glipizide and then insulin glargine upon failure to achieve HbA1c <6.5%, or (2) initial triple therapy with metformin/pioglitazone/ exenatide. Each patient received 75-gram OGTT prior to start of therapy...
August 3, 2021: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/34140791/risk-of-thyroid-cancer-associated-with-use-of-liraglutide-and-other-antidiabetic-drugs-in-a-us-commercially-insured-population
#19
JOURNAL ARTICLE
Donnie Funch, Kathleen Mortimer, Najat J Ziyadeh, John D Seeger, Li Zhou, Eva Ng, Douglas Ross, Atheline Major-Pedersen, Heidrun Bosch-Traberg, Helge Gydesen, David D Dore
BACKGROUND: Quantify association between the glucagon-like peptide-1 receptor agonist liraglutide and risk of thyroid cancer (TC) compared to other antidiabetics. PATIENTS AND METHODS: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US health plan (2010-2014) and followed for a median of 17 months. Thyroid cancer cases during follow-up were identified via a validated algorithm...
2021: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/34047443/comparative-efficacy-of-glucose-lowering-medications-on-body-weight-and-blood-pressure-in-patients-with-type-2-diabetes-a-systematic-review-and-network-meta-analysis
#20
JOURNAL ARTICLE
Apostolos Tsapas, Thomas Karagiannis, Panagiota Kakotrichi, Ioannis Avgerinos, Chrysanthi Mantsiou, Georgios Tousinas, Apostolos Manolopoulos, Aris Liakos, Konstantinos Malandris, David R Matthews, Eleni Bekiari
AIM: To compare the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes. METHODS: We searched Medline, Embase, the Cochrane Library, and grey literature sources until 29 September 2020 for randomized controlled trials of at least 24 weeks' duration assessing the effects of glucose-lowering drugs on body weight and blood pressure in adults with type 2 diabetes. We performed frequentist network meta-analyses and calculated weighted mean differences and 95% confidence intervals combining trial arms of different approved doses of a given intervention into a single group...
September 2021: Diabetes, Obesity & Metabolism
keyword
keyword
43271
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.